trending Market Intelligence /marketintelligence/en/news-insights/trending/EMhtdwc91c5SUaa-EFgfIQ2 content esgSubNav
In This List

MaxCyte closes £20M placing

Blog

Insight Weekly: US inflation soars; real estate faces slowdown; megadeals drive tech M&A

Blog

Commercial Banking: June 22nd Edition

Blog

Understanding Loss Given Default A Review of Three Approaches

Blog

Insight Weekly: Path to net-zero; US manufacturing momentum; China's lithium M&A frenzy


MaxCyte closes £20M placing

MaxCyte Inc. closed a share placement to raise about £20 million in gross proceeds for its CARMA platform.

The company issued 7,275,000 shares at £2.75 apiece with Panmure Gordon acting as the financial adviser, nominated adviser and broker to the company.

Completion of the placement is subject to shareholder approval.

The CARMA platform is meant to help the company develop treatments for ovarian cancer and acute myeloid leukemia, a type of blood cancer. It will also be used to develop treatments for other indications.